Research

LIke ThisLIke ThisLIke This

Jason Dearling, PhD

Man no face
Department:
Radiology Research
Division
Hospital Title:
Staff Scientist
Academic Title:
Instructor in Radiology, Havard Medical School
Contact Via Email
Send an email to SendYour Name*Your Email Address*Subject*Comments*

Research Overview

Jason Dearling’s research focuses on the use of biomolecules to detect, describe and treat tissue disease.  New imaging probes, therapy agents and regimes developed by Dr. Dearling are now in clinical use. 

Dr. Dearling’s current focus is to develop new detection and treatment approaches for cancer metastases.  Specifically, he is working on the radiolabeling and preclinical evaluation of antibodies that bind to neuroblastoma cells.  This will enable the quantification and characterization of neuroblastoma tumors through medical imaging (PET/CT) to guide treatment, and he is working with colleagues at St. Jude Children’s Research Hospital to take this approach into the clinic. 

In addition to this core project, he is involved in a number of other disease areas, including:
- Working with colleagues at Dana-Farber Cancer Institute to develop a new approach for the detection and therapy of Ewing’s Sarcoma.  
- Through the development of new proteins, peptides and targeted liposomes, he is developing a theranostic approach to detect and quantify colitis, and to treat it with siRNA.  
- The early detection of tissue rejection is crucial in the clinical decision making that follows cardiac transplant, and he is working with colleagues at BCH to develop new ways of detecting transplant blood flow, vascularization, immune cell invasion and rejection.  

Due to the wide applicability of the work in his laboratory, Dr. Dearling also acts as a consultant to the biomedical community through the imaging core, “Imogen”.  This core provides a mechanism for probe and model development, imaging, and data analysis.

About Jason Dearling

Jason Dearling received his PhD degree from the University of Kent.  He studied the structure-activity relationship between small molecules and their whole-body and intratumoral distribution, leading to the hypoxia tracer Cu-ATSM.  He then studied tumor biology with Professors R. Barbara Pedley and Richard Begent at University College London with the specific aim of quantifying the effect of the tumor microenvironment on targeted radiation therapy of colorectal cancer.  This work led to combination therapies that are now in clinical trials.  He then moved to Boston to work with Drs. Alan Packard and Stephan Voss at Harvard Medical School and Boston Children’s Hospital on another highly therapy-resistant cancer, neuroblastoma, where his objective is to develop an individualized approach to treating these patients by preventing the growth of metastases that arise after initial therapy.

Key Publications

Specific uptake of 99mTc-NC100692, an αvβ3-targeted imaging probe, in subcutaneous and orthotopic tumors. Dearling JL, Barnes JW, Panigrahy D, Zimmerman RE, Fahey F, Treves ST, Morrison MS, Kieran MW, Packard AB. Nucl Med Biol. 2013 Aug;40(6):788-94. 

Detection of intestinal inflammation by MicroPET imaging using a (64)Cu-labeled anti-beta(7) integrin antibody. Dearling JL, Park EJ, Dunning P, Baker A, Fahey F, Treves ST, Soriano SG, Shimaoka M, Packard AB, Peer D. Inflamm Bowel Dis. 2010 Sep;16(9):1458-66. 

Localization of radiolabeled anti-CEA antibody in subcutaneous and intrahepatic colorectal xenografts: influence of tumor size and location within host organ on antibody uptake. Dearling JL, Flynn AA, Qureshi U, Whiting S, Boxer GM, Green A, Begent RH, Pedley RB. Nucl Med Biol. 2009 Nov;36(8):883-94. 

Combining radioimmunotherapy with antihypoxia therapy 2-deoxy-D-glucose results in reduction of therapeutic efficacy. Dearling JL, Qureshi U, Begent RH, Pedley RB. Clin Cancer Res. 2007 Mar 15;13(6):1903-10.

Analysis of the regional uptake of radiolabeled deoxyglucose analogs in human tumor xenografts. Dearling JL, Flynn AA, Sutcliffe-Goulden J, Petrie IA, Boden R, Green AJ, Boxer GM, Begent RH, Pedley RB. J Nucl Med. 2004 Jan;45(1):101-7.

Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. Dearling JL, Lewis JS, Mullen GE, Welch MJ, Blower PJ. J Biol Inorg Chem. 2002 Mar;7(3):249-59.

Publications

Publications powered by Harvard Catalyst Profiles
  1. Dearling JL, Daka A, Veiga N, Peer D, Packard AB. Colitis ImmunoPET: Defining Target Cell Populations and Optimizing Pharmacokinetics. Inflamm Bowel Dis. 2016 Mar; 22(3):529-38.
  2. Dearling JL, Packard AB. On the destiny of (copper) species. J Nucl Med. 2014 Jan; 55(1):7-8.
  3. Rajkumar V, Dearling JL, Packard A, Pedley RB. Radioimmunotherapy: optimizing delivery to solid tumors. Ther Deliv. 2011 May; 2(5):567-72.
  4. Violet JA, Dearling JL, Green AJ, Begent RH, Pedley RB. Fractionated 131I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice. Br J Cancer. 2008 Aug 19; 99(4):632-8.
  5. Fidarova EF, El-Emir E, Boxer GM, Qureshi U, Dearling JL, Robson MP, Begent RH, Trott KR, Pedley RB. Microdistribution of targeted, fluorescently labeled anti-carcinoembryonic antigen antibody in metastatic colorectal cancer: implications for radioimmunotherapy. Clin Cancer Res. 2008 May 1; 14(9):2639-46.
  6. El Emir E, Qureshi U, Dearling JL, Boxer GM, Clatworthy I, Folarin AA, Robson MP, Nagl S, Konerding MA, Pedley RB. Predicting response to radioimmunotherapy from the tumor microenvironment of colorectal carcinomas. Cancer Res. 2007 Dec 15; 67(24):11896-905.
  7. Dearling JL, Pedley RB. Technological advances in radioimmunotherapy. Clin Oncol (R Coll Radiol). 2007 Aug; 19(6):457-69.
  8. El-Emir E, Dearling JL, Huhalov A, Robson MP, Boxer G, Neri D, van Dongen GA, Trachsel E, Begent RH, Pedley RB. Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models. Br J Cancer. 2007 Jun 18; 96(12):1862-70.
  9. Dearling JL, Qureshi U, Begent RH, Pedley RB. Combining radioimmunotherapy with antihypoxia therapy 2-deoxy-D-glucose results in reduction of therapeutic efficacy. Clin Cancer Res. 2007 Mar 15; 13(6):1903-10.
  10. El-Emir E, Boxer GM, Petrie IA, Boden RW, Dearling JL, Begent RH, Pedley RB. Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice. Eur J Cancer. 2005 Mar; 41(5):799-806.
  11. Show all
  12. Green A, Flynn A, Pedley RB, Dearling J, Begent R. Nonuniform absorbed dose distribution in the kidney: the influence of organ architecture. Cancer Biother Radiopharm. 2004 Jun; 19(3):371-7.
  13. Mayer A, Tsiompanou E, Flynn AA, Pedley RB, Dearling J, Boden R, Begent RH. Higher dose and dose-rate in smaller tumors result in improved tumor control. Cancer Invest. 2003 Jun; 21(3):382-8.
  14. Flynn AA, Pedley RB, Green AJ, Dearling JL, El-Emir E, Boxer GM, Boden R, Begent RH. The nonuniformity of antibody distribution in the kidney and its influence on dosimetry. Radiat Res. 2003 Feb; 159(2):182-9.
  15. Pedley RB, El-Emir E, Flynn AA, Boxer GM, Dearling J, Raleigh JA, Hill SA, Stuart S, Motha R, Begent RH. Synergy between vascular targeting agents and antibody-directed therapy. Int J Radiat Oncol Biol Phys. 2002 Dec 1; 54(5):1524-31.
  16. Petrie IA, Flynn AA, Pedley RB, Green AJ, El-Emir E, Dearling JL, Boxer GM, Boden R, Begent RH. Spatial accuracy of 3D reconstructed radioluminographs of serial tissue sections and resultant absorbed dose estimates. Phys Med Biol. 2002 Oct 21; 47(20):3651-61.
  17. Southworth R, Dearling JL, Medina RA, Flynn AA, Pedley RB, Garlick PB. Dissociation of glucose tracer uptake and glucose transporter distribution in the regionally ischaemic isolated rat heart: application of a new autoradiographic technique. Eur J Nucl Med Mol Imaging. 2002 Oct; 29(10):1334-41.
  18. Flynn AA, Green AJ, Pedley RB, Boxer GM, Dearling J, Watson R, Boden R, Begent RH. A model-based approach for the optimization of radioimmunotherapy through antibody design and radionuclide selection. Cancer. 2002 Feb 15; 94(4 Suppl):1249-57.
  19. Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R, Dearling J, Chaplin DJ, Begent RH. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res. 2001 Jun 15; 61(12):4716-22.
  20. Flynn AA, Pedley RB, Green AJ, Boxer GM, Boden R, Dearling J, Bhatia J, Begent RH. Effectiveness of radiolabelled antibodies for radio-immunotherapy in a colorectal xenograft model: a comparative study using the linear--quadratic formulation. Int J Radiat Biol. 2001 Apr; 77(4):507-17.
  21. Lewis JS, Dearling JL, Sosabowski JK, Zweit J, Carnochan P, Kelland LR, Coley HM, Blower PJ. Copper bis(diphosphine) complexes: radiopharmaceuticals for the detection of multi-drug resistance in tumours by PET. Eur J Nucl Med. 2000 Jun; 27(6):638-46.
  22. Dearling J. The carrot and its role in the promotion of breastfeeding. Pract Midwife. 1999 Jan; 2(1):19-20.
  23. Dearling JL, Lewis JS, Mullen GE, Rae MT, Zweit J, Blower PJ. Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med. 1998 Jul; 25(7):788-92.
  24. Cunningham D, Evans C, Gazet JC, Ford H, Pople A, Dearling J, Chappell D, Coombes C. Comparison of antiemetic efficacy of domperidone, metoclopramide, and dexamethasone in patients receiving outpatient chemotherapy regimens. Br Med J (Clin Res Ed). 1987 Jul 25; 295(6592):250.
  25. Dearling JL, Lewis JS, Mullen GE, Welch MJ, Blower PJ. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J Biol Inorg Chem. 2002 Mar; 7(3):249-59.
  26. Dearling JL, Flynn AA, Sutcliffe-Goulden J, Petrie IA, Boden R, Green AJ, Boxer GM, Begent RH, Pedley RB. Analysis of the regional uptake of radiolabeled deoxyglucose analogs in human tumor xenografts. J Nucl Med. 2004 Jan; 45(1):101-7.
  27. Dearling J. Euthanasia. Euthanasia already exists. BMJ. 2001 Oct 6; 323(7316):809.
  28. Dearling JL, Voss SD, Dunning P, Snay E, Fahey F, Smith SV, Huston JS, Meares CF, Treves ST, Packard AB. Imaging cancer using PET--the effect of the bifunctional chelator on the biodistribution of a (64)Cu-labeled antibody. Nucl Med Biol. 2011 Jan; 38(1):29-38.
  29. Dearling JL, Park EJ, Dunning P, Baker A, Fahey F, Treves ST, Soriano SG, Shimaoka M, Packard AB, Peer D. Detection of intestinal inflammation by MicroPET imaging using a (64)Cu-labeled anti-beta(7) integrin antibody. Inflamm Bowel Dis. 2010 Sep; 16(9):1458-66.
  30. Dearling JL, Packard AB. PET-radioimmunodetection of integrins: imaging acute colitis using a 64Cu-labeled anti-ß7 integrin antibody. Methods Mol Biol. 2012; 757:487-96.
  31. Voss SD, Smith SV, DiBartolo N, McIntosh LJ, Cyr EM, Bonab AA, Dearling JL, Carter EA, Fischman AJ, Treves ST, Gillies SD, Sargeson AM, Huston JS, Packard AB. Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugates. Proc Natl Acad Sci U S A. 2007 Oct 30; 104(44):17489-93.
  32. Vavere AL, Butch ER, Dearling JL, Packard AB, Navid F, Shulkin BL, Barfield RC, Snyder SE. 64Cu-p-NH2-Bn-DOTA-hu14.18K322A, a PET radiotracer targeting neuroblastoma and melanoma. J Nucl Med. 2012 Nov; 53(11):1772-8.
  33. Dearling JL, Packard AB. Some thoughts on the mechanism of cellular trapping of Cu(II)-ATSM. Nucl Med Biol. 2010 Apr; 37(3):237-43.
  34. Dearling JL, Flynn AA, Qureshi U, Whiting S, Boxer GM, Green A, Begent RH, Pedley RB. Localization of radiolabeled anti-CEA antibody in subcutaneous and intrahepatic colorectal xenografts: influence of tumor size and location within host organ on antibody uptake. Nucl Med Biol. 2009 Nov; 36(8):883-94.
  35. Lankester KJ, Maxwell RJ, Pedley RB, Dearling JL, Qureshi UA, El-Emir E, Hill SA, Tozer GM. Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down. Int J Oncol. 2007 Feb; 30(2):453-60.
  36. Dearling JL, Barnes JW, Panigrahy D, Zimmerman RE, Fahey F, Treves ST, Morrison MS, Kieran MW, Packard AB. Specific uptake of 99mTc-NC100692, an avß3-targeted imaging probe, in subcutaneous and orthotopic tumors. Nucl Med Biol. 2013 Aug; 40(6):788-94.
  37. O'Neill AF, Dearling JL, Wang Y, Tupper T, Sun Y, Aster JC, Calicchio ML, Perez-Atayde AR, Packard AB, Kung AL. Targeted imaging of Ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody. Clin Cancer Res. 2014 Feb 1; 20(3):678-87.
  38. Dearling JL, Paterson BM, Akurathi V, Betanzos-Lara S, Treves ST, Voss SD, White JM, Huston JS, Smith SV, Donnelly PS, Packard AB. The ionic charge of copper-64 complexes conjugated to an engineered antibody affects biodistribution. Bioconjug Chem. 2015 Apr 15; 26(4):707-17.
  39. Daly KP, Dearling JL, Seto T, Dunning P, Fahey F, Packard AB, Briscoe DM. Use of [18F]FDG Positron Emission Tomography to Monitor the Development of Cardiac Allograft Rejection. Transplantation. 2015 Sep; 99(9):e132-9.
LIke ThisLIke ThisLIke This
Close